Theranos CEO Elizabeth Holmes is expected to speak at the American Association for Clinical Chemistry’s annual meeting on Aug. 1 in Philadelphia and present data on the embattled company’s technologies. But, as STAT reports, it is unclear how much Holmes will divulge as the company has no peer-reviewed data and is facing scrutiny from the federal government.
Holmes’s appearance will be the first time she will have publicly discussed Theranos’s technologies, which include a device to collect blood through a finger prick. On July 7, the Centers for Medicare & Medicaid Services (CMS) barred Holmes from owning, operating or directing a laboratory for at least two years after inspecting one of Theranos’s laboratories in Newark, California. CMS also revoked the company’s certification for that laboratory.
Read the full STAT article below: